Cronos Group Inc

Most Recent

  • uploads///weed _
    Company & Industry Overviews

    Here’s What Jim Cramer Had to Say about the Cronos-Altria Deal

    Jim Cramer said Altria’s acquisition of a 45% stake in Cronos Group last week was a “smart move” for Altria.

    By Adam Jones
  • uploads///Uhhled
    Earnings Report

    Cronos Group Invests in the Future

    Through Cronos Group’s partnership with Ginko Bioworks, the company aims to produce cannabis through fermentation.

    By Adam Jones
  • uploads///
    Company & Industry Overviews

    Checking On Canopy Growth and Its Peers

    Canopy Growth is one of the strongest players in the cannabis industry with a market cap of ~24 billion Canadian dollars.

    By Adam Jones
  • uploads///Forward EV to Sales
    Miscellaneous

    Does Cronos Group Look Expensive Compared to Its Peers?

    Cronos Group (CRON) has been on a declining trend for a while. The stock rose to a peak of ~30 Canadian dollars in February.

    By Adam Jones
  • uploads///AdobeStock_
    Company & Industry Overviews

    Top Developments in the Cannabis Industry’s Early Years

    In the second half of 2018, the cannabis industry remained busy. As the cannabis sector experienced a boom, there was a lot of excitement among investors.

    By Adam Jones
  • uploads///Altria
    Company & Industry Overviews

    Altria’s Dividend Yield Gets More Attractive

    On August 23, the markets tumbled due to the escalating trade war. The S&P 500 Index lost around 2.6%. Altria stock held out and lost just 0.4%.

    By Rekha Khandelwal, CFA
  • uploads///Aurora Cannabis
    Cannabis

    Aurora Cannabis’s Revenue: Here’s What Analysts Expect

    Aurora Cannabis is set to release its fiscal 2020 first-quarter earnings results on November 11. Let’s see what analysts expect for its upcoming quarter.

    By Sushree Mohanty
  • uploads///AdobeStock_
    Cannabis

    Aurora Cannabis’s Price Target Cut by 30%

    Aurora Cannabis (ACB) stock is currently down 29.23% on the NYSE on a YTD (year-to-date) basis. The company has lost 14.81% of its value since October 1.

    By Margaret Patrick
  • uploads///can_
    Cannabis

    Cannabis Legalization: Four Governors Met in New York

    The Day reported that New York, New Jersey, Connecticut, and Pennsylvania’s governors met and agreed on basic guidelines for legalizing marijuana.

    By Rajiv Nanjapla
  • uploads///pot stocks
    Cannabis

    Cannabis Investment: How to Buy ACB, CGC, and Other Stocks

    Cannabis is a hot sector that’s constantly evolving. Right now, how to buy cannabis stocks is a question that’s likely on many investors’ minds.

    By Sushree Mohanty
  • uploads///Mexico
    Cannabis

    Mexico Will Attempt to Legalize Marijuana in 2020

    Mexico is ready with a revised proposal to legalize marijuana this year. The Supreme Court gave lawmakers until April 30 to submit the new proposal.

    By Sushree Mohanty
  • uploads///green _
    Company & Industry Overviews

    Tilray Invests in ROSE LifeScience

    On December 14, Tilray (TLRY) announced that it’s investing in ROSE LifeScience—a cannabis producer in Quebec.

    By Adam Jones
  • uploads///cannabis _
    Company & Industry Overviews

    Revisiting Valuation Multiples for Cannabis Companies

    Recreational cannabis is close to being legalized in Canada, and producers are running at full bore to capture a piece of the market.

    By Adam Jones
  • uploads///hemp _
    Company & Industry Overviews

    Cannabis Sector Closes Positively in the Week Ended April 13

    Last week (ended April 13), overall market sentiment was positive, with the S&P 500 rising 2% and the TSX 30 gaining 44 basis points.

    By Adam Jones
  • uploads///Canopy_
    Cannabis

    Can Canopy Beat Q2 Estimates and Boost the Sector?

    This week is important for the cannabis sector, as Canopy Growth and Aurora Cannabis are both set to report their earnings results on November 14.

    By Rajiv Nanjapla
  • uploads///Cronos group
    Cannabis

    Cronos Group Joins Altria to Bet on Cannabidiol Market

    Cannabis company Cronos Group has expanded its presence in the US cannabidiol market through a tie-up with tobacco company Altria Group.

    By Sushree Mohanty
  • uploads///mariju
    Cannabis

    Marijuana Vape Products Expected in Alberta Stores

    AGLC will allow retail stores in Alberta to sell marijuana vape products. Consumers will likely be able to purchase cannabis vape products in the next two weeks.

    By Rajiv Nanjapla
  • uploads///arnel hasanovic oWSXdeASg unsplash
    Cannabis

    Why Canopy Growth Isn’t Happy with Apple

    Apple removed 181 vaping-related apps due to the vape crisis in the US. Canopy Growth is not happy with Apple’s move. Let’s see why.

    By Sushree Mohanty
  • uploads///aurora cannabis
    Cannabis

    Aurora Cannabis: What to Expect from Its Q4 Results

    Aurora Cannabis should report its fourth-quarter earnings results on Thursday. So far, September has been positive. As of Monday, the stock has gained 8.7%.

    By Sushree Mohanty
  • Cannabis

    Marijuana Legalization Continues: Wisconsin Steps Up!

    Marijuana laws are pretty strict in Wisconsin. Although cannabis is spreading its roots across US states, it’s still illegal at the federal level. President Trump and his administration want states to decide. Florida, New York, and Minnesota are all gearing up to legalize adult-use cannabis. Now, Wisconsin is pushing to legalize medical marijuana. Let’s see […]

    By Adam Jones
  • uploads///Cannabis
    Macroeconomic Analysis

    Gundlach Compares Cannabis to Bitcoin

    Jeffrey Gundlach predicted bitcoin’s (BTC) crash after the cryptocurrency’s peak in December 2017.

    By Anuradha Garg
  • uploads///canopy growth cannabis
    Cannabis

    Canopy Growth: New Cannabis 2.0 Products amid COVID-19

    Canopy Growth (NYSE:CGC)(TSE:WEED) still has investors’ attention despite all that the marijuana industry has gone through.

    By Sushree Mohanty
  • uploads///Medical cannabis
    Cannabis

    Medical Cannabis in Brazil Is Coming

    According to a Reuters report on December 3, Brazil is ready to approve medical cannabis products. Currently, cannabis is illegal in Brazil.

    By Sushree Mohanty
  • uploads///cannabis _
    Cannabis

    How Cannabis Stocks Fared Last Week

    Tilray was the top performer in the cannabis sector last week with a rise of 49% as a result of better-than-expected second-quarter earnings and guidance.

    By Adam Jones
  • uploads///marijuana
    Cannabis

    Marijuana: Will Trump Have an Edge over Biden?

    With Biden strongly opposing full-scale legalization, President Trump could turn around things. President Trump might support medical marijuana legalization.

    By Sushree Mohanty
  • uploads///vaping
    Cannabis

    Vaping Concerns Grow, FDA and FTC Investigate Juul

    Vaping has become very popular. However, investigations by the FTC and FDA sparked more concerns. Juul’s vaping devices could cause seizures.

    By Sushree Mohanty
  • uploads///Aphria
    Cannabis

    Aphria: Why Jefferies Recommends a ‘Buy’

    Aphria (APHA) reported its results for the first quarter of fiscal 2020 on October 15. Since then, the stock has fallen 7%.

    By Sushree Mohanty
  • uploads///Canopy
    Cannabis

    Canopy Gets Estimates Revised by Analysts for 2020

    Canopy Growth (CGC) (WEED) missed analysts’ estimates this year. Analysts had huge expectations from CGC after Canada allowed cannabis in 2018.

    By Sushree Mohanty
  • uploads///AdobeStock_
    Cannabis

    Valuation for Cannabis Stocks in October

    The cannabis industry is fighting against the ongoing US-China trade war and recessionary worries, which have hurt valuations across the global market.

    By Margaret Patrick
  • uploads///Cronos
    Cannabis

    Analysts’ Outlook for Cronos Group in January

    Jefferies reduced the target price for Cronos Group stock to $5.3 from $7.5. The stock’s average target price is set at 12.0 Canadian dollars.

    By Sushree Mohanty
  • uploads///cannabis
    Cannabis

    Cannabis in Kansas: Residents Are Taking Action

    Currently, 33 states and Washington, D.C., have legalized medical cannabis, but it’s illegal in Kansas. Even having a small amount is considered a crime.

    By Sushree Mohanty
  • uploads///canopy
    Cannabis

    Canopy Growth Gets an Upgrade, Constellation Books Losses

    Canopy Growth (CGC) (WEED) received optimistic views from analysts on Monday. Seaport Global Securities upgraded the stock to “buy” from “neutral.”

    By Sushree Mohanty
  • uploads///Joe Biden
    Cannabis

    Joe Biden Won’t Legalize Cannabis—Why?

    Although Joe Biden supported medical cannabis in his previous presidential campaigns, he has always opposed full-scale legalization.

    By Sushree Mohanty
  • uploads///matthias wagner QrqeusbpFMM unsplash
    Cannabis

    Why Canopy Growth Is Partnering with Drake

    The Canadian Press reported that Canopy Growth is partnering with rapper Drake to launch a new cannabis venture, the More Life Growth Company.

    By Sushree Mohanty
  • uploads///CNTTF
    Company & Industry Overviews

    CannTrust Holdings’ Stock Grew ~11% Last Week

    On January 25, CannTrust Holdings’ (CNTTF) stock price closed at $6.87, ~5.19% higher than its closing price of $6.53 on January 24 and ~11% higher than its closing price of $6.21 on January 18.

    By Daniel Collins
  • uploads///marijuana _
    Company & Industry Overviews

    How Cannabis Companies Are Rushing to Expand Operations

    In anticipation of recreational cannabis’s legalization at the federal level in Canada, provinces have been doing their best to prepare.

    By Adam Jones
  • uploads///cannabis
    Cannabis

    Cannabis Beverages: Why Canadians Can’t Wait

    Deloitte estimates that the newly legalized cannabis beverage market could be worth 529 million Canadian dollars annually in Canada.

    By Sushree Mohanty
  • uploads///CGC_
    Cannabis

    Why Does Jim Cramer Prefer CGC versus CRON?

    Canopy Growth (NYSE:CGC) lost 25.4% in 2019. The company reported weak sales and higher-than-expected operating losses in the last two quarters.

    By Rajiv Nanjapla
  • uploads///cannabis edibles
    Cannabis

    No Cannabis Edibles in Three Provinces for Christmas

    After Canada legalized cannabis edibles in October, consumers hoped to buy these products this month. However, three provinces must wait until January.

    By Sushree Mohanty
  • uploads///marijuana _
    Company & Industry Overviews

    How Cannabis Stocks Performed Last Week

    Strong sentiment in the cannabis sector pushed cannabis ETFs and stocks into positive territory last week.

    By Adam Jones
  • uploads///AdobeStock_
    Cannabis

    Was CGC a Big Mistake for Constellation Brands?

    Canopy Growth (CGC) has seen dizzying ups and gloomy downs in 2019. The stock jumped up by 79.91% from $28.92 on January 2 to $52.03 on April 29.

    By Margaret Patrick
  • uploads///herb _
    Company & Industry Overviews

    Canopy Growth to Get Extract Supply from MediPharm Labs

    On November 29, Canopy Growth (WEED) entered an 18-month supply agreement with MediPharm Labs.

    By Adam Jones
  • uploads///Canopy Growth
    Cannabis

    What’s Canopy Growth Strategy for Growth?

    Canopy Growth has struggled this year. Despite all their strategies, cannabis companies have failed to hit revenue and profitability targets this year.

    By Sushree Mohanty
  • uploads///IIPR
    Basic Materials

    IIPR, CRON, TLRY Surging: A Good Day for Cannabis Stocks

    It looks like cannabis stocks had a great day. Innovative Industrial Properties (IIPR), Cronos Group (CRON), and Tilray (TLRY) are all surging today.

    By Sushree Mohanty
  • uploads///Aurora Cannabis
    Cannabis

    Aurora Cannabis: Is This the Right Time to Invest?

    Amid a subdued cannabis sector, Aurora Cannabis (ACB) stock has taken a serious hit and is down 36.4% this month. Is this the right time to invest?

    By Sushree Mohanty
  • uploads///Tilray
    Cannabis

    Tilray’s Q2 Earnings Are Out: Did It Impress?

    In its Q2 earnings report today, Tilray reported a 371% YoY revenue increase to $45.9 million. Tilray beat analysts’ estimate of $41.1 million in revenue.

    By Sushree Mohanty
  • uploads///Aphria
    Cannabis

    Has Irwin Simon Really Turned Aphria Around?

    Aphria (APHA) has impressed investors with its earnings results this year. Overall, the cannabis industry has struggled due to various headwinds.

    By Sushree Mohanty
  • uploads///Republicans
    Cannabis

    Do Republicans Want to Join the Cannabis Action?

    Republicans have been conservative about cannabis. However, cannabis legalization is a popular discussion topic among Democrats.

    By Sushree Mohanty
  • uploads///Aphria
    Cannabis

    Aphria: Analysts’ Target Price and Ratings

    While Aphria’s consensus target price fell after its earnings, most analysts remain bullish on the stock. The overall “strong-buy” rating didn’t change.

    By Sushree Mohanty
  • uploads///
    Cannabis

    Medical Cannabis: NH Lawmakers Revoke Governor’s Veto

    New Hampshire legalized medical cannabis, but using cannabis for recreational purposes is still prohibited. The state legalized medical marijuana in 2013.

    By Rajiv Nanjapla
  • uploads///marijuanaI
    Cannabis

    New Year Will Bring Legal Marijuana to Illinois Residents

    Marijuana products are top-rated among Americans. Illinois will see recreational marijuana products for sale on January 1.

    By Sushree Mohanty
  • uploads///Bruce Linton
    Cannabis

    Bruce Linton Gives Tips to Canopy’s New CEO

    Bruce Linton, ex-CEO of Canopy Growth (CGC) (WEED), recently had some tips to share with the company’s recently appointed CEO, David Klein.

    By Sushree Mohanty
  • uploads///cannabis
    Cannabis

    Raymond James Foresees a Cannabis Rebound in 2020

    Cannabis stocks had a difficult 2019. Besides cannabis companies losing out on revenue and profitability, many external factors also affected the sector. While pessimism drove the industry this year, a Raymond James analyst predicts things can turn around in 2020. Let’s take a look. Raymond James feels the cannabis sector could rebound On December 16, […]

    By Sushree Mohanty
  • uploads///marijuana _
    Company & Industry Overviews

    Why Tilray Cannabis Stock Popped Today

    On September 18, cannabis stock Tilray (TLRY) popped about 27% to an all-time high of $153.8 in the mid-day session.

    By Adam Jones
  • uploads///Pennsylvania
    Cannabis

    Marijuana Legalization Ramps Up: Is Pennsylvania Next?

    Marijuana legalization is ramping up in the US. Pennsylvania legalized medical cannabis in 2016. Now, the state wants to legalize recreational cannabis.

    By Sushree Mohanty
  • uploads///Aphria
    Cannabis

    Analysts Neutral on Aphria’s 2020 Outlook in December

    Aphria has successfully impressed investors compared to other cannabis companies this year, even though the same factors have affected the entire industry.

    By Sushree Mohanty
  • uploads///Part  IIPR
    Company & Industry Overviews

    IIPR Stock Moves Higher after New Debt Is Raised

    Last week, Innovative Industrial Properties (IIPR) offered $125 million in senior notes, giving initial investors the option to exercise $18.75 million in additional principal amount notes.

    By Peter Neil
  • uploads///Tilray Since Inception
    Company & Industry Overviews

    Tilray Expands in Latin America

    On October 9, Tilray (TLRY) announced that it completed the acquisition of a distribution company in Latin America, which it says will help the company produce and market medical cannabis-based products in Chile and the rest of Latin America.

    By Adam Jones
  • uploads///Forward EV to EBITDA Multiple for Cannabis Companies
    Company & Industry Overviews

    Cannabis Stocks’ Valuation Multiples in October: A Comparison

    Tilray’s (TLRY) multiple was 536.4x, a month-over-month increase of 88% from 284.9x.

    By Adam Jones
  • uploads///ACB_
    Cannabis

    Aurora Cannabis Releases Update on Cannabis 2.0

    Aurora Cannabis (ACB) is going through a rough patch. This year, the company’s stock has lost 60.9% of its value as of December 23.

    By Rajiv Nanjapla
  • uploads///AdobeStock_
    Cannabis

    What’s the Market Potential for CBD?

    The FDA has issued warning letters to 15 companies involved in illegal sales of non-psychoactive CBD products. What’s the legal market’s potential?

    By Margaret Patrick
  • uploads///CRON_
    Cannabis

    Cronos Group Receives Rare ‘Buy’ Rating from MKM Partners

    MKM Partners analyst Bill Kirk likes Cronos Group’s healthy cash position, strong track record, and its relationship with Altria (NYSE:MO).

    By Rajiv Nanjapla
  • uploads///south dakota marijuana
    Cannabis

    Marijuana Legalization in South Dakota Lies with Voters Now

    Marijuana legalization in South Dakota could see daylight in 2020. The state passed measures to legalize both recreational and medical marijuana.

    By Sushree Mohanty
  • uploads///cannabis
    Company & Industry Overviews

    Cannabis Stocks: Will Tough Times End Soon?

    Cannabis players are having a hard time this year. Regulatory concerns and weaker earnings due to the vaping-related crisis took a toll on the sector.

    By Sushree Mohanty
  • uploads///Cannabis
    Cannabis

    Cannabis: Will Top Companies’ Earnings Be a Relief?

    The cannabis earnings season has started again. Earnings season is an exciting time for investors who have been eyeing the sector.

    By Sushree Mohanty
  • uploads///marijuana _
    Company & Industry Overviews

    One Chart That Shows What Makes Cannabis Attractive to Altria

    As the cannabis space has increasingly become crowded, companies such as Cronos Group would greatly benefit from a company such as Altria.

    By Adam Jones
  • uploads///Canopy Growth_
    Cannabis

    When Will Canopy Growth Become Profitable?

    Canopy Growth reported a negative EBITDA of 92.1 million Canadian dollars in the first quarter of fiscal 2020. The EBITDA fell 69.2% in the second quarter.

    By Rajiv Nanjapla
  • uploads///canopy growth buy
    Cannabis

    Must-Know: Is Canopy Growth Still a Buy?

    For fiscal 2020, analysts expect Canopy Growth to report revenues of 404.5 million Canadian dollars—a rise of 78.7% from fiscal 2019.

    By Rajiv Nanjapla
  • uploads///Tilray Gets US Governments Approval Importing CBD
    Cannabis

    Tilray Gets US Government’s Approval to Import CBD

    On August 8, Tilray announced that it had received approval to import cannabis into the US to conduct two clinical trials related to cannabidiol.

    By Adam Jones
  • uploads///Cannabis
    Cannabis

    How Cannabis Retail’s First Year Shook Out

    Recreational cannabis has been legally available to Canadians since October 2018, when Canada legalized it. Recently, the country rolled out Cannabis 2.0.

    By Sushree Mohanty
  • uploads///log _
    Company & Industry Overviews

    Canopy Growth Moves to Acquire Hiku Brands Company

    On July 10, Canopy Growth (WEED) (CGC) announced that it had entered an agreement to acquire Hiku Brands Company (HIKU).

    By Adam Jones
  • uploads///MedMen
    Cannabis

    MedMen: Analysts’ Views before Its Earnings

    MedMen’s disappointing fourth-quarter results caused the stock price to fall. The company missed analysts’ revenue estimates for the quarter.

    By Sushree Mohanty
  • uploads///cannabis
    Cannabis

    Are Cannabis Edibles Coming to Maryland Soon?

    Recreational cannabis isn’t legal in Maryland, but the state has been trying to launch edibles as part of its medical marijuana program.

    By Sushree Mohanty
  • uploads///Can_ceo
    Cannabis

    Why Canopy Growth’s New CEO Popped the Stock

    Yesterday, Canopy Growth (CGC) (WEED) announced that it appointed Constellation Brands’ (STZ) CFO David Klein as its new CEO.

    By Rajiv Nanjapla
  • uploads///cannabis
    Cannabis

    Raymond James Is Cautiously Optimistic about Cannabis Stocks

    So far, cannabis stocks have rebounded in 2020, which investors expected. The marijuana industry struggled in 2019. Overall, the rebound will take time.

    By Sushree Mohanty
  • uploads///Hexo
    Cannabis

    Will Hexo Continue to Struggle in 2020?

    For the second quarter of fiscal 2020, analysts expect Hexo’s revenue to grow 25.5% YoY (year-over-year) to 16.8 million Canadian dollars.

    By Sushree Mohanty
  • uploads///cannabis sales
    Cannabis

    Cannabis Sales Decline Across Canada—Why?

    In October, Canada completed the second phase of recreational cannabis legalization. This was expected to help drive sales. But that hasn’t been the case.

    By Sushree Mohanty
  • uploads///Jim Cramer
    Cannabis

    Why Does Jim Cramer Like Cronos Group and Aphria?

    Cronos Group and Aphria are Jim Cramer’s top picks in the cannabis sector. Aphria’s upbeat earnings results restored investors’ faith in the sector.

    By Sushree Mohanty
  • uploads///Forward EV to EBITDA Multiple for Cannabis Companies
    Company & Industry Overviews

    Comparing Cannabis Stocks’ Valuation Multiples in November

    Aurora Cannabis (ACB) was trading at a multiple of 26.4x, which declined from 34x in October.

    By Adam Jones
  • uploads///cannabis
    Cannabis

    Cannabis Corruption in the US: Trouble before Elections?

    Cannabis legalization has taken a back seat in the US. Since the last Democratic debate, there hasn’t been much discussion about federal legalization.

    By Sushree Mohanty
  • uploads///AdobeStock_
    Cannabis

    Canopy Growth: Analysts’ Target Prices and Ratings

    Macro-economic and political uncertainty across the global market have already taken a toll on Canopy Growth stock (CGC) (WEED).

    By Margaret Patrick
  • uploads///bud _
    Miscellaneous

    Jim Cramer’s Recommendations in the Cannabis Industry

    Cramer pointed investors to Canopy Growth (WEED) (CGC), the Canadian cannabis (HMMJ) giant, because of its backing from Constellation Brands.

    By Adam Jones
  • uploads///Marijuana
    Cannabis

    Vermont Could See Marijuana Sales in 2020

    Marijuana is legal in Vermont for medical and recreational use. However, there are some limitations. The state doesn’t allow marijuana sales yet.

    By Sushree Mohanty
  • uploads///aurora cannabis q results announce
    Cannabis

    Aurora Cannabis: Q3 Revenue Beat the Estimates

    Aurora Cannabis saw less of an impact from COVID-19 in the third quarter. Cannabis is an essential item amid the pandemic.

    By Sushree Mohanty
  • uploads///marijuana montana
    Cannabis

    Marijuana Legalization Proceeds in Montana amid COVID-19

    New Approach Montana resumed its marijuana legalization campaign in May. The group submitted plenty of signatures and qualified for the November ballot.

    By Sushree Mohanty
  • uploads///AdobeStock_
    Consumer

    Will Altria’s Q2 Earnings Be a Boom or Bust?

    Analysts expect Altria to report revenues of $5.08 billion in the second quarter of 2020—a fall of 2.2% from $5.19 billion in the second quarter of 2019.

    By Rajiv Nanjapla
  • cbd stocks to watch
    Cannabis

    Investment Radar — Top CBD Stocks to Watch

    By Sushree Mohanty
  • uploads///Marijuana
    Cannabis

    Will Coronavirus Target the Marijuana Industry Next?

    Cannabis companies that have operations in China, especially the ones that manufacture vape products, have been impacted by the coronavirus.

    By Sushree Mohanty
  • uploads///innovative industrial properties cash
    Cannabis

    Innovative Industrial Properties Raises More Cash amid Crisis

    On June 30, Innovative Industrial Properties announced its decision to raise additional capital of $225 million through a public offering of its common stock.

    By Sushree Mohanty
  • uploads///AdobeStock_
    Consumer

    Barclays Downgrades Altria, Worries about Declining Market Share

    Today, Gaurav Jain of Barclays downgraded Altria Group (NYSE:MO) from “overweight” to “equal weight.” He also lowered his target price from $50 to $43.

    By Rajiv Nanjapla
  • uploads///dea
    Cannabis

    Analyzing the Top 3 CBD Companies to Buy in July

    Charlotte’s Web Holdings (NYSEARCA:CWEB) is one of the main players in the CBD business. The company plans to keep expanding in 2020.

    By Rajiv Nanjapla
  • uploads///AdobeStock_
    Cannabis

    Cronos and Altria’s Deal: Does It Make Sense Now?

    Cronos Group, one of the more resilient cannabis stocks, hasn’t escaped the gloom in the cannabis sector. It’s down 37.44% year-to-date on the Nasdaq.

    By Margaret Patrick
  • uploads///Organigram
    Cannabis

    Haywood Capital Markets Reduced OrganiGram’s Target Price

    OrganiGram (NASDAQ:OGI) stock is trading higher before its third-quarter earnings. The stock closed with a gain of 3.9% at $1.58 on Wednesday.

    By Sushree Mohanty
  • uploads///marijuana stocks july
    Cannabis

    What to Expect from Marijuana Stocks in July

    OrganiGram will likely report its earnings for the third quarter of fiscal 2020 on July 13. We’ll have to see if marijuana stocks recover in July.

    By Sushree Mohanty
  • uploads///Acb_
    Cannabis

    Why Did Raymond James Downgrade OrganiGram?

    On Monday, Cantech Letter reported that Raymond James downgraded OrganiGram from an “outperform” rating to a “market perform” rating.

    By Rajiv Nanjapla
  • uploads///cronos group raymond james bullish
    Cannabis

    Why Is Raymond James Bullish on Cronos Group?

    Earlier this week, Rahul Sarugaser of Raymond James upgraded Cronos Group (NASDAQ:CRON) from “market perform” to “outperform.”

    By Rajiv Nanjapla
  • uploads///aurora cannabis analysts bullish
    Cannabis

    Aurora Cannabis’s Cost-Cutting Measures Made Analysts Bullish

    Aurora Cannabis (NYSE:ACB) announced some business transformation plans on June 23. The plans included cost savings and margin improvement.

    By Sushree Mohanty
  • uploads///virgin islands marijuana legalization
    Cannabis

    U.S. Virgin Islands’ Governor Supports Marijuana Legalization

    While most businesses suffered amid COVID-19, marijuana saw a drastic rise in sales. Many states have been rethinking the benefits of marijuana legalization.

    By Sushree Mohanty
  • uploads///hexo mixed results
    Cannabis

    Hexo Beat the Revenue Estimates, Posted Q3 Loss

    Hexo beat the revenue estimates of 19.9 million Canadian dollars. However, the company reported a quarterly EBITDA loss of 4.3 million Canadian dollars.

    By Sushree Mohanty
  • uploads///hexo pass
    Cannabis

    Why Lorne Steinberg Thinks Hexo Is a Pass

    Lorne Steinberg thinks that even after Hexo’s deal with Molson Coors, it still doesn’t look attractive. He would rather find value somewhere else.

    By Sushree Mohanty
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.